The word "hematology" referred first in 1748 with publication of Thomas Schwenke's book, Haematologia, a "treatise as compete as it could then be, upon the blood considered in its state of health and of disease" (1). From then on, tremendous efforts put forth to evolve hematology with the influences in application of novel diagnostic technologies, genetic revolution, and molecular mechanisms to lighten the challenges in pathogenesis of diseases. In the current Research Topic, we aimed to update the community on the new era in hematology which included state-of-the-art knowledge in all fields of hematology including recent diagnostic technologies, novel treatment approaches of malign/benign hematological diseases and unsolved issues.Anemia, the reduction in hemoglobin (Hb) or hematocrit (HCT) or red blood cell, is the most common blood disorder. Research is going on for methods of detection, genetic and molecular aspects in pathophysiology as well as treatment approaches.Voxelotor is an HBs polymerization inhibitor approved by FDA where it demonstrated an improved Hb level, and reduced hemolysis, with an improved rate of vaso-oclusive crises (2). Alkindi and colleagues defined the abnormal HbD variant on high-performance liquid chromatography (HPLC) in patients under Voxelotor that will provide data on patient compliance. Β-thalassemia is another inherited hemoglobin disorder mainly effecting Mediterranean area, North and Central Africa, Southeast Asia, and the Middle East (3). Granulocyte transfusions (GCs) are potential therapy for neutropenic patients with infections resistant to antibiotics and anti-fungal drugs (10). Fernandes and colleagues investigated unknown points in various manufacturing strategies of granulocyte transfusions by evaluating leukocyte composition, neutrophil viability, calcium mobilization, chemotaxis, phagocytosis, reactive oxygen species, cytokine production and metabolites. G-CSF GCs contained more neutrophils than prednisone GCs.
Prednisone GC neutrophils showed enhanced phagocytosis and G-CSF GC neutrophils exhibited decreased chemotaxis but increased IL-8 production. G-CSF neutrophils seemed to be more sensitive to storage. Review by Castagna et al lightens up a controversial issue in the care of relapsed/refractory aggressive lymphomas (large B-cell lymphoma and MCL) by results obtained after allo-HSCT and CAR T cell therapies.In summary, today, excessive data have been accumulated in malign and benign hematology. Novel diagnostic and methods sculpture the concept of 'personalized medicine' rather than conventional approach.
